Probing the Magic Role of NAD+ Metabolism-associated Genes in Gastric Cancer

Probing the Magic Role of NAD+ Metabolism-associated Genes in Gastric Cancer


1. Introduction

Gastric cancer (GC) represents a global health-care challenge, which is the fifth most common cancer and the fourth leading cause of cancer death across the world in 2020, with a significant incidence rate. Despite the efficacy of improved chemotherapy and surgical options, the prognosis of GC patients remains unsatisfactory.

Remarkably, NAD+ is an intriguing target for cancer therapy by leverage of its impacts upon energy metabolism and pathway regulation. This research is engineered to probe into the magic roles of NAD+ metabolism-associated genes (NMRGs) in GC.

2. The establishment of prognostic risk model for GC patients

Based on the expression levels of NAD+ metabolism-related genes in GC cell lines, a prognostic model is established for GC patients. 

Simply put, a total of 13 lncRNAs related to NMRGs are singled out by LASSO regression to construct prognostic risk model, with seven markedly up-regulated lncRNAs and six prominently down-regulated lncRNAs in GC tissues, as confirmed by real-time polymerase chain reaction. On this basis, six lncRNAs with the minimum likelihood of deviance corresponding to the first-rank value of Log (k) are chosen, followed by the plotting of model AUC and calculation of the risk score. The detailed calculation formula is listed below: risk score = AL139147.1 × (0.416) + AC107021.2 × (0.3119) + AC090825.1 × (0.1218) + AC005726.2 × (−0.0.0062) + AC012615.1 × (−0.0130) + AP001107.6 × (−0.0451). It is found that patients with high-risk scores have a poor prognosis.

3. The correlation between immune factors and risk scores

The levels of immune cell infiltration, including CD8 T cells, CD4 naïve T cells, CD4 memory-activated T cells, B memory cells, and naïve B cells, are markedly associated with risk scores. Besides, high-risk patients show activated immune checkpoints as well as high immune and stromal scores. 

4. The role of NAD+ in the metabolism of GC patients

NAD+ not only promotes GC progression, but also promotes immune cell infiltration into tumors. The modulation of NAD+ is significant for the metabolism of GC patients.

5. Conclusion

NMRGs may be promising biomarkers for predicting clinical outcomes of GC patients and ultimately facilitating their precise management. 


Sun, X., Wen, H., Li, F., Bukhari, I., Ren, F., Xue, X., Zheng, P., & Mi, Y. (2023). NAD+ associated genes as potential biomarkers for predicting the prognosis of gastric cancer. Oncology research, 32(2), 283–296.


BONTAC has rich R&D experience and advanced technology in the biosynthesis of NAD and NMN. Bonzyme whole-enzymatic method is adopted, which is environmental-friendly, with no harmful solvent residues. The purity of products can reach up to 95%, which is benefited from the exclusive Bonpure seven-step purification technology. BONTAC has self-owned factories and has obtained a number of international certifications, where high quality and stable supply of products can be ensured. BONTAC has over 170 domestic and foreign patents, leading the industry of coenzyme and natural products.


This article is based on the reference in the academic journal. The relevant information is provide for sharing and learning purposes only, and does not represent any medical advice purposes. If there is any infringement, please contact the author for deletion. The views expressed in this article do not represent the position of BONTAC. 

Under no circumstances will BONTAC be held responsible or liable in any way for any claims, damages, losses, expenses, costs or liabilities whatsoever (including, without limitation, any direct or indirect damages for loss of profits, business interruption or loss of information) resulting or arising directly or indirectly from your reliance on the information and material on this website.


Get In Touch

Recommend Read

Leave Your Message